Nanotechnology based approaches to fight against COVID 19 infection
Nanotechnology, the study of nanoparticles, is emerging as a leading pharmaceutical technique. It is used in various fields of drug delivery, bioimaging, biomedical diagnosis, tissue engineering, production of formulation, medical devices and many others, thereby playing a key role in future pharmaceutical and pharmacotherapy production. The ability to modify molecules and supramolecular frameworks for the development of devices or substances with altered functions or features is the most significant benefit of this technology. Nanoscience provides a solution to the spread of COVID-19 infection by aiding in its detection, including surface antiviral coatings, protection of facemasks, increased personal protection services, airborne filtration and therapeutic administration. Addressing the numerous clinical and wellbeing issues that have arisen as a result of the global dissemination of coronavirus infection. This study explores in depth the different uses of this technology in combating the pandemic situation of COVID-19 with an insight into the creation of a chemically engineered nanodevice that prevents its proliferation in the host cells. Low medication loading capability, low loading performance, and poor ability to monitor the delivery of sizes are the only problems with existing approaches. The use of nanotechnology, such as nanopatterning, could allow high loading efficiency and highly homogeneous particle sizes to generate nano / micro particles.
2. Kinam Park K. Nanotechnology: What it can do for drug delivery. J. Control Release. 2007; 120(1-2):1-3.
3. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003; 21:1184–1191.
4. Jain K K. The role of nanobiotechnology in drug discovery Drug Discov. Today. 2005; 10:1435–1442.
5. Alonso M J. Nanomedicine for overcoming biological barriers Biomed. Pharmacother. 2004;58: 168–172.
6. Moghimi S M, Hunter A C, Murray J C. Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 2001; 53: 283–318.
7. Vasir J K, Maram M K, Labhasetwar V. D. Nanosystems in drug targeting: opportunities and challenges Curr. Nanosci.2005; 1:47–67.
8. Datta R., Jaitawat S. Nanotechnology - the new frontier of medicine. Med. J. Armed Forces India. 2006; 62(3):263–268.
9. Kohane D.S. Microparticles and nanoparticles for drug delivery. Biotechnol. Bioeng. 2007;96(2):203–209.
10. Alexis F., Pridgen E. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008;5(4):505–515.
11. Khalil N., Carraro E. Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin., Drug Deliv. 2011;8(1):95–112.
12. Cheng Y., Zhao L. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem. Soc. Rev. 2011;40(5):2673–2703.
13. Liu M, Kono K, Fréchet JM. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J. Control Release. 2000; 65: 121-125.
14. S. M. Moghimi A. C. Hunter J. C. Murray. Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 2001; 53:283–318.
15. Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr. Opin. Colloid Interface Sci. 2009; 14(1):3–15.
16. Aggarwal B.B., Van Kuiken M.E. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp. Biol. Med. 2009; 234(8):825–849.
17. Buzea, C., Pacheco, I.I. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007; 2(4), 17-71.
18. Angra P.K., Rizvi S.A.A. Novel approach for preparing nontoxic stealth microspheres for drug delivery. Eur. J. Chem. 2011; 2:125–129.
19. Bantz C., Koshkina O. The surface properties of nanoparticles determine the agglomeration state and the size of the particles under physiological conditions. Zellner, R., ed. Beilstein J. Nanotechnol. 2014; 5:1774-1786.
20. Khanbabaie R., Jahanshahi M. Revolutionary impact of nanodrug delivery on neuroscience. Curr. Neuropharmacol. 2012; 10(4):370–392.
21. Emerich D.F., Thanos C. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 2006; 23:171-184.
22. Catania A., Barrajón-Catalán E. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res. Treat. 2013;1:55-65.
23. N. Venkatesan J. Yoshimitsu Y. Ito N. Shibata K. Takada. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics Biomaterials. 2005; 26:7154-7163.
24. A. Bianco K. Costarelos M. Prato. Applications of carbon nanotubes in drug delivery Curr. Opin. Chem. Biol. 2005; 9:674–679.
25. Kapetanovic I.M., Muzzio M. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011; 68:593–601.
26. Kelly C., Jefferies C. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;5:671-76.
27. Dinesh B., Bianco A. Designing multimodal carbon nanotubes by covalent multi-functionalization. Nanoscale. 2016; 8(44):18596–18611.
28. Catania A., Barrajón-Catalán E. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res. Treat. 2013; 1:55–65.
29. Calvo P., Remuñan-López C. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 1997; 14:1431–6143.
30. Kou L., Sun J. The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J. Pharm. Sci. 2013;8:1–10.
31. Xu Wang, Lily Yang, MD, Zhuo Chen, Dong M, Shin MD. Application of Nanotechnology in Cancer Therapy and Imaging CA Cancer J. Clin. 2008; 58:97-110.
32. I. Brigger C. Dubernet P. Couvreur. Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 2002; 54:631–651.
33. Baker J.R., Jr. Dendrimer-based nanoparticles for cancer therapy. Hematol. Am. Soc. Hematol. Educ. Program. 2009:708–719.
34. Baudino T.A. Targeted cancer therapy: the next generation of cancer treatment. Curr. Drug Discov. Technol. 2015; 12(1):3–20.
35. Bhojani M.S., Van Dort M. Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol. Pharm. 2010; 7(6):1921–1929.
36. Biswas, A.K., Islam, M.R. Nanotechnology based approaches in cancer therapeutics. Adv. Nat. Sci.: Nanosci. Nanotechnol. 2014; 5:143-151.
37. Chavanpatil M.D., Khdair A. Polymer-surfactant nanoparticles for sustained release of water-soluble drugs. J. Pharm. Sci. 2007; 96(12):3379–3389.
38. Chen Z., Mao R. Fullerenes for cancer diagnosis and therapy: preparation, biological and clinical perspectives. Curr. Drug Metab. 2012;13(8):1035-1045.
39. Emerich D.F., Thanos C.G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target. 2007; 15(3):163–183.
40. Kolluru L.P., Rizvi S.A.A. Formulation development of albumin based theragnostic nanoparticles as a potential tumor targeting and delivery system. J. Drug Target. 2013; 21:77–86.
41. Labhasetwar V., Song C. Arterial uptake of biodegradable nanoparticles: effect of surface modifications.J. Pharm. Sci. 1998; 87:1229–1234.
42. Li D., Kaner R.B. Shape and aggregation control of nanoparticles: not shaken. Not Stirred. J. Am. Chem. Soc. 2006; 128(3):968-975.
43. Lee J.H., Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem Eng Sci. 2015; 125:75–84.
44. Liebler D.C., Guengerich F.P. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov.2005; 4(5):410-420.
45. Liu R., Kay B.K. Nanoparticle delivery: targeting and nonspecific binding. MRS Bull. 2009; 34(6):432-440.
46. Pathak N, Pathak P. Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review. Int J Drug Reg Affairs [Internet]. 2019Mar.16 [cited 2020Dec.13];7(1):53-8. Available from:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM